Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia

Leuk Lymphoma. 2020 Jan;61(1):225-227. doi: 10.1080/10428194.2019.1648805. Epub 2019 Aug 5.

Authors

Shin Yeu Ong¹, Colin Phipps², Chandramouli Nagarajan¹, Tiffany Tang³, Soon Thye Lim³, Yeow Tee Goh¹, Yuh Shan Lee²

Affiliations

¹ Department of Haematology, Singapore General Hospital, Singapore.
² Parkway Cancer Centre, Singapore.
³ National Cancer Center, Singapore.

PMID: 31379229
DOI: 10.1080/10428194.2019.1648805

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Asia
Bone Marrow
Central Nervous System Neoplasms*
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Neoplasm Recurrence, Local